Solubilization of flurbiprofen into aptamer-modified PEG-PLA micelles for targeted delivery to brain-derived endothelial cells in vitro

Journal of Microencapsulation

Volumn 30, Issue 7, 2013, Pages 701-708

  Mu, Chaofeng ^a   Dave, Nimita ^a   Hu, Jing ^a   Desai, Pankaj ^a   Pauletti, Giovanni ^a   Bai, Shuhua ^b   Hao, Jiukuan ^a  

^a UNIVERSITY OF CINCINNATI   (United States)

^b HUSSON UNIVERSITY   (United States)

Author keywords

Alzheimer's disease; Aptamer; Brain targeting; Flurbiprofen; Micelles; PEG PLA; Solubilization; Transferrin receptor

Indexed keywords

APTAMER; FLURBIPROFEN; MACROGOL; POLYLACTIC ACID; TRANSFERRIN RECEPTOR;

ALZHEIMER DISEASE; ANIMAL CELL; ARTICLE; BRAIN CELL; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG INDICATION; DRUG SOLUBILITY; ENDOTHELIUM CELL; EVAPORATION; FLUORESCENCE SPECTROSCOPY; IN VITRO STUDY; MICELLE; MOUSE; NONHUMAN; SOLUBILIZATION;

ALZHEIMER DISEASE; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; APTAMERS, NUCLEOTIDE; BASE SEQUENCE; BRAIN; CELL LINE; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; ENDOTHELIAL CELLS; FLURBIPROFEN; MICE; MICELLES; POLYETHYLENE GLYCOLS; RECEPTORS, TRANSFERRIN;

EID: 84885351606     PISSN: 02652048     EISSN: 14645246     Source Type: Journal    
DOI: 10.3109/02652048.2013.778907     Document Type: Article

References (37)

1. Abdul-Hay SO, Luo J, Ashghodom RT, Thatcher GR. NO-flurbiprofen reduces amyloid-beta, is neuroprotective in cell culture, and enhances cognition in response to cholinergic blockade. J Neurochem, 2009;111: 766-76.
2. Anderson BD, Conradi RA. Predictive relationships in the water solubility of salts of a nonsteroidal anti-inflammatory drug. J Pharm Sci, 1985;74:815-20.
3. Bhattacharya R, Osburg B, Fischer D, Bickel U. Targeted delivery of complexes of biotin-PEG-polyethylenimine and NF-kappaB decoys to brain-derived endothelial cells in vitro. Pharm Res, 2008;25:605-15.
4. Bickel U, Yoshikawa T, Landaw EM, Faull KF, Pardridge WM. Pharmacologic effects in vivo in brain by vector-mediated peptide drug delivery. Proc Natl Acad Sci USA, 1993;90:2618-22.
5. Bickel U, Yoshikawa T, Pardridge WM. Delivery of peptides and proteins through the blood-brain barrier. Adv Drug Deliv Rev, 2001;46:247-79.
6. Blanco E, Bey EA, Dong Y, Weinberg BD, Sutton DM, Boothman DA, Gao J. Beta-lapachone-containing PEG-PLA polymer micelles as novel nanotherapeutics against NQO1-overexpressing tumor cells. J Control Release, 2007;122:365-74.
7. Boado RJ, Zhang Y, Zhang Y, Pardridge WM. Genetic engineering, expression, and activity of a fusion protein of a human neurotrophin and a molecular Trojan horse for delivery across the human blood-brain barrier. Biotechnol Bioeng, 2007;97:1376-86.
8. Chang M, Yang CS, Huang DM. Aptamer-conjugated DNA icosahedral nanoparticles as a carrier of doxorubicin for cancer therapy. ACS Nano, 2011;5:6156-63.
9. Chen CH, Dellamaggiore KR, Ouellette CP, Sedano CD, Lizadjohry M, Chernis GA, Gonzales M, Baltasar FE, Fan AL, Myerowitz R, et al. Aptamer-based endocytosis of a lysosomal enzyme. Proc Natl Acad Sci USA, 2008;105:15908-13.
10. Cho H, Kwon GS. Polymeric micelles for neoadjuvant cancer therapy and tumor-primed optical imaging. ACS Nano, 2011;5:8721-9.
11. Descamps L, Dehouck MP, Torpier G, Cecchelli R. Receptor-mediated transcytosis of transferrin through blood-brain barrier endothelial cells. Am J Physiol, 1996;270:H1149-58.
12. Ellington AD, Szostak JW. In vitro selection of RNA molecules that bind specific ligands. Nature, 1990;346:818-22.
13. Farokhzad OC, Jon S, Khademhosseini A, Tran TN, Lavan DA, Langer R. Nanoparticle-aptamer bioconjugates: A new approach for targeting prostate cancer cells. Cancer Res, 2004;64:7668-72.
14. Friden PM, Walus LR, Watson P, Doctrow SR, Kozarich JW, Backman C, Bergman H, Hoffer B, Bloom F, Granholm AC. Blood-brain barrier penetration and in vivo activity of an NGF conjugate. Science, 1993; 259:373-7.
15. Gasparini L, Ongini E, Wenk G. Non-steroidal anti-inflammatory drugs (NSAIDs) in Alzheimer's disease: Old and new mechanisms of action. J Neurochem, 2004;91:521-36.
16. Gaucher G, Dufresne MH, Sant VP, Kang N, Maysinger D, Leroux JC. Block copolymer micelles: Preparation, characterization and application in drug delivery. J Control Release, 2005; 109:169-88.
17. Geerts H. Drug evaluation: (R)-flurbiprofen-an enantiomer of flurbiprofen for the treatment of Alzheimer's disease. IDrugs, 2007; 10:121-33.
18. Gu F, Zhang L, Teply BA, Mann N, Wang A, Radovic-Moreno AF, Langer R, Farokhzad OC. Precise engineering of targeted nanoparticles by using self-assembled biointegrated block copolymers. Proc Natl Acad Sci USA, 2008;105:2586-91.
19. Kurihara A, Deguchi Y, Pardridge WM. Epidermal growth factor radiopharmaceuticals: In chelation, conjugation to a blood-brain barrier delivery vector via a biotin-polyethylene linker, pharmacokin-etics, and in vivo imaging of experimental brain tumors. Bioconjug Chem, 1999;10:502-11.
20. Lee SW, Yun MH, Jeong SW, In CH, Kim JY, Seo MH, Pai CM, Kim SO. Development of docetaxel-loaded intravenous formulation, Nanoxel-PM using polymer-based delivery system. J Control Release, 2011;155: 262-71.
21. Lu J, Owen SC, Shoichet MS. Stability of self-assembled polymeric micelles in serum. Macromolecules, 2011;44:6002-8.
22. Madaio MP, Hodder S, Schwartz RS, Stollar BD. Responsiveness of autoimmune and normal mice to nucleic acid antigens. J Immunol, 1984;132:872-6.
23. Miller T, Rachel R, Besheer A, Uezguen S, Weigandt M, Goepferich A. Comparative investigations on in vitro serum stability of polymeric micelle formulations. Pharm Res, 2012;29:448-59.
24. Moos T. Immunohistochemical localization of intraneuronal transferrin receptor immunoreactivity in the adult mouse central nervous system. J Comp Neurol, 1996;375:675-92.
25. Mu CF, Balakrishnan P, Cui FD, Yin YM, Lee YB, Choi HG, Yong CS, Chung SJ, Shim CK, Kim DD. The effects of mixed MPEG-PLA/Pluronic copolymer micelles on the bioavailability and multidrug resistance of docetaxel. Biomaterials, 2010;31:2371-9.
26. Pignatello R, Panto V, Salmaso S, Bersani S, Pistara V, Kepe V, Barrio JR, Puglisi G. Flurbiprofen derivatives in Alzheimer's disease: Synthesis, pharmacokinetic and biological assessment of lipoamino acid prodrugs. Bioconjug Chem, 2008;19:349-57.
27. Richy F, Rabenda V, Mawet A, Reginster JY. Flurbiprofen in the symptomatic management of rheumatoid arthritis: A valuable alternative. Int J Clin Pract, 2007;61:1396-406.
28. Rovensky J, Micekova D. Six-month prospective study to monitor the treatment of rheumatic diseases with sustained-release flurbiprofen. Drugs Exp Clin Res, 2000;26:19-24.
29. Sarpietro MG, Pitarresi G, Ottimo S, Giuffrida MC, Ognibene MC, Fiorica C, Giammona G, Castelli F. Interaction between drug loaded polyaspartamide- polylactide-polysorbate based micelles and cell membrane models: A calorimetric study. Mol Pharm, 2011;8:642-50.
30. Shao K, Huang R, Li J, Han L, Ye L, Lou J, Jiang C. Angiopep-2 modified PE-PEG based polymeric micelles for amphotericin B delivery targeted to the brain. J Control Release, 2010;147:118-26.
31. Shen J, Zhan C, Xie C, Meng Q, Gu B, Li C, Zhang Y, Lu W. Poly(ethylene glycol)-block-poly(D, L-lactide acid) micelles anchored with angiopep-2 for brain-targeting delivery. J Drug Target, 2011;19: 197-203.
32. van Houten M, Posner, BI. Insulin binds to brain blood vessels in vivo. Nature, 1979;282:623-5.
33. Wang Y, Yang T, Wang X, Wang J, Zhang X, Zhang Q. Targeted polymeric micelle system for delivery of combretastatin A4 to tumor vasculature in vitro. Pharm Res, 2010;27:1861-8.
34. Xiong MP, Yanez JA, Kwon GS, Davies NM, Forrest ML. A cremophor-free formulation for tanespimycin (17-AAG) using PEO-b-PDLLA micelles: Characterization and pharmacokinetics in rats. J Pharm Sci, 2009;98:1577-86.
35. Yu MK, Kim D, Lee IH, So JS, Jeong YY, Jon S. Image-guided prostate cancer therapy using aptamer-functionalized thermally cross-linked superparamagnetic iron oxide nanoparticles. Small, 2011;7:2241-9.
36. Zhang Y, Schlachetzki F, Pardridge WM. Global non-viral gene transfer to the primate brain following intravenous administration. Mol Ther, 2003a;7:11-18.
37. Zhang YF, Boado RJ, Pardridge, WM. Absence of toxicity of chronic weekly intravenous gene therapy with pegylated immunoliposomes. Pharm Res, 2003b;20:1779-85.